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Kidney disease is one of the most serious manifestations of systemic lupus erythematosus (SLE). Despite the improvement in
the medical care of SLE in the past two decades, the prognosis of lupus nephritis remains unsatisfactory. Besides exploring
more eﬀective but less toxic treatment modalities that will further improve the remission rate, early detection and treatment
of renal activity may spare patients from intensive immunosuppressive therapies and reduce renal damage. Conventional clinical
parameters such as creatinine clearance, proteinuria, urine sediments, anti-dsDNA, and complement levels are not sensitive or
speciﬁc enough for detecting ongoing disease activity in the lupus kidneys and early relapse of nephritis. Thus, novel biomarkers
are necessary to enhance the diagnostic accuracy and sensitivity of lupus renal disease, prognostic stratiﬁcation, monitoring of
treatment response, and detection of early renal ﬂares. This paper reviews promising biomarkers that have recently been evaluated
in longitudinal studies of lupus nephritis.
1.Introduction
Glomerulonephritis is one of the commonest and most
serious manifestations of systemic lupus erythematosus
(SLE) [1, 2]. Renal involvement in SLE carries signiﬁcant
morbidity and mortality. The 5- and 10-year renal survival
rates of lupus nephritis in the 1990s range between 83%–
92% and 74–84%, respectively [3]. The prognosis of lupus
nephritis is particularly bad in certain ethnic groups such as
the Africans and Hispanics [4].
Despite the overall improvement in the care of SLE in the
past two decades, the prognosis of lupus nephritis remains
unsatisfactory. Up to 25% of patients still develop end stage
renal failure 10 years after onset of renal disease [5]. In
order to improve the prognosis of lupus nephritis further,
newer strategies with better eﬃcacy but lower toxicities
are necessary. This can be achieved by modiﬁcation of
existing regimens, combination strategies, or more speciﬁc
targeting at the immunopathogenetic pathways by novel
biological agents such as rituximab, belimumab, abatacept,
and abetimus [6]. However, to the disappointment of the
lupus community, data from recent clinical trials on targeted
therapies of SLE are discouraging. While the clinical and
immunological heterogeneity of SLE and ﬂaws in study
design and outcome measures may contribute to the futility
of these trials, more sensitive and speciﬁc clinical markers
for the onset or relapse of renal disease activity in patients
with SLE may allow earlier institution of treatment and even
preventive strategies so that the eﬃcacy of existing therapies
can be enhanced while treatment-related complications can
be minimized. In addition to the reﬁnement of outcome
assessment tools in SLE, inclusion of novel biomarkers as
surrogate end-points in future lupus nephritis clinical trials
may increase the feasibility of identiﬁcation of subsets of
patients who would beneﬁt most from the newer regimens.
2. Unmet Needs for Novel Biomarkersin
LupusNephritis
Current laboratory markers for lupus nephritis such as pro-
teinuria, urine protein-to-creatinine ratio, creatinine clear-
ance, anti-dsDNA, and complement levels are unsatisfactory.
They lack sensitivity and speciﬁcity for diﬀerentiating renal
activity and damage in lupus nephritis. Signiﬁcant kidney
damage can occur before renal function is impaired and ﬁrst
detection by laboratory parameters. Persistent proteinuria
may not necessarily indicate ongoing inﬂammation in the2 Journal of Biomedicine and Biotechnology
kidneys and may be contributed by pre-existing chronic
lesions or recent damage in the kidneys during the course
of the disease. Flares of nephritis can occur without any
observable and recent increase in the degree of proteinuria.
Renal biopsy is the gold standard for providing information
on the histological classes of lupus nephritis and the relative
degree of activity and chronicity in the glomeruli. However,
it is invasive and serial biopsies that are impractical in the
monitoring of lupus nephritis. Thus, novel biomarkers that
are able to discriminate lupus renal activity and its severity,
predict renal ﬂares, and monitor treatment response and
disease progress are clearly necessary.
A biomarker refers to a biologic, biochemical, or molec-
ular event that can be assayed qualitatively and quantitatively
by laboratory techniques. The levels of biomarkers should
correlate with disease pathogenesis or activity in diﬀerent
organsystems.Anidealbiomarkerforlupusnephritisshould
possess the following properties: (1) good correlation with
renal activity as reﬂected by the degree of proteinuria and
urine sediments, (2) sensitive to change so that it can be
used for serial monitoring of disease activity in the kidneys
and deﬁning treatment response and clinical remission, (3)
ability to predict renal activity/ﬂares before an obvious
change in conventional clinical parameters occurs so that
early treatment/preventive strategies can be considered, (4)
speciﬁc to nephritis among patients with SLE, and (5)
speciﬁc to SLE for aiding early diagnosis of lupus nephritis.
In addition, a useful biomarker should be easy to assay,
simple to interpret, and readily available in most laboratories
with a reasonable cost.
Hitherto, quite a number of serum and urine biomarkers
have been studied in lupus nephritis. Most of these markers
have only been tested in cross-sectional studies and only
a few have been evaluated in longitudinal studies. The
number of patients having been tested is relatively small
and the results have not been conﬁrmed by independent
groups of investigators. Even for biomarkers that have
been prospectively evaluated, further validation has to be
performed in larger groups of patients with lupus nephritis.
In this paper, biomarkers that have been recently studied
in lupus nephritis are systematically reviewed. Information
is grouped under three subheadings: (1) biomarkers that
correlate with SLE renal activity in longitudinal studies, (2)
biomarkers that correlate with lupus nephritis activity in
cross-sectional studies, and (3) biomarkers that correlate
with renal histology or prognosis of lupus nephritis.
3.Biomarkers That Correlate with Lupus Renal
ActivityinLongitudinalStudies
3.1. Chemokines. Monocyte chemoattractant protein-
1 (MCP-1) is a leukocyte chemotactic factor that is
involved in mediating inﬂammation and injury in lupus
nephritis [7]. In murine models of lupus nephritis, genetic
depletion or blockade of MCP-1 ameliorates glomerular and
interstitial inﬂammation and hence renal damage [8, 9].
In human lupus nephritis, increased expression of MCP-1
on endothelial cells, renal epithelial cells, and inﬁltrating
mononuclear cells in the tubulointerstitial regions can be
demonstrated by immunohistochemical staining and in situ
hybridization [10].
Level of MCP-1 in urine is increased in patients with a
variety of glomerulonephritis and correlates with the extent
of proteinuria and the severity of glomerular lesions [11].I n
patients with SLE, urine MCP-1 levels are elevated in those
with active nephritis and reduced after immunosuppressive
treatment [10, 12]. A number of recent cross-sectional
s t u d i e sh a v ec o n ﬁ r m e dt h a tl e v e l so fu r i n eM C P - 1a r e
elevated in patients with active lupus nephritis compared to
those with inactive renal disease or healthy controls [13–15].
Rovin et al. [14] studied a cohort of adult SLE and
measured urinary MCP-1 (uMCP-1) levels at the time of
lupus ﬂares and when available, before and after these ﬂares.
T h em e a nu M C P - 1l e v e la tt h et i m eo fr e n a lﬂ a r e sw a s
signiﬁcantly higher than that of healthy controls, patients
with inactive renal disease and patients with active or
inactive nonrenal SLE. As uMCP-1 level did not correlate
with nonrenal SLE activity, it was likely to be speciﬁc
for renal activity. In addition, uMCP-1 was also found to
be a sensitive indicator for renal ﬂare, with 73% of the
ﬂare values above the 95th percentile of disease controls.
uMCP-1 levels were higher in patients with proliferative
(WHO class III or IV) than membranous (class V) nephritis.
There was no relationship between the cumulative amount
of immunosuppressive therapies received within 30 days
preceding a renal ﬂare and uMCP-1 levels. In longitudinal
follow-up of 12 patients, uMCP-1 increased as early as 2 to
4 months before renal ﬂares. uMCP-1 levels remained high
for at least 4 months after treatment of ﬂares. In patients
who improved clinically, uMCP-1 levels fell to control levels,
whereasinpatientswhowererefractorytotreatment,uMCP-
1 remained high. Some patients had persistently elevated
uMCP-1 despite improvement in proteinuria, suggesting
the possibility of ongoing subclinical inﬂammation in the
kidneys.
Similar ﬁndings of uMCP-1 in lupus nephritis were
reported by Tian et al. [16]. In this study, 73 patients
with diﬀuse proliferative lupus nephritis were followed.
After an observation of 2 years, 22 patients experienced
renal ﬂares. Patients experiencing renal ﬂares showed higher
levels of MCP-1 in their urine samples. Using a diﬀerent
approach, Chan et al. [17] prospectively examined the
expression of chemokine mRNAs in urinary sediments of 9
patients with active lupus nephritis for 24 weeks. The major
component of urinary sediments is renal tubular epithelial
cells and leukocytes (predominantly T cells) that make up
only a quarter of the sediments. It was demonstrated that
urinary mRNA expression of MCP-1 and other chemokines
correlated signiﬁcantly with SLE disease activity scores and
anti-dsDNA titers during the course of immunosuppressive
treatment.
Overall, uMCP-1 is a promising biomarker for lupus
nephritis. It is speciﬁc for renal activity, sensitive to predict
renal ﬂares and correlates with severity of ﬂares and prolifer-
ative types of lupus nephritis. However, further longitudinal
validationofuMCP-1inlargercohortsofpatientswithlupus
n e p h r i t i si sn e c e s s a r y .Journal of Biomedicine and Biotechnology 3
3.2. Neutrophil Gelatinase-Associated Lipocalin (NGAL).
Lipocalin-2 is a small glycosylated protein produced in
many tissues and organs. Lipocalin-2 was ﬁrst described
in human neutrophil granules as neutrophil gelatinase-
associated lipocalin (NGAL). NGAL belongs to a family of
carrierproteinsthatareimportantforcellularirontransport,
apoptosis, bacteriostasis, and tissue diﬀerentiation. NGAL
is constitutively expressed at low levels in the kidneys [18]
but upregulated following acute renal injury and various
insults such as inﬂammation, ischemia, and infection [19–
22]. An early rise in urinary and plasma NGAL levels after
cardiopulmonary bypass surgery in children is predictive
of acute kidney injury with high sensitivity and speciﬁcity
[23]. In addition, serum and urine NGAL levels correlate
with residual glomerular ﬁltration rate better than serum
creatinine and are good biomarkers for chronic kidney
disease [24, 25]. A recent work has shown that NGAL
expressionwasdramaticallyupregulatedinkidneymesangial
cells derived from lupus-prone mice after in vitro treatment
with the murine nephritogenic anti-dsDNA monoclonal
antibodies [26].
Two cross-sectional studies have examined the relation-
ship between NGAL levels and human lupus nephritis [27,
28]. Brunner et al. [27] reported higher levels of urine
NGAL levels (adjusted for urinary creatinine) in pediatric
patients with SLE compared to juvenile idiopathic arthritis.
Subgroup analysis showed that the diﬀerence of urine
NGAL (uNGAL) levels was only signiﬁcant between patients
with biopsy-proven lupus nephritis and idiopathic arthritis.
uNGAL levels correlated with urine protein-to-creatinine
ratios and were associated with renal SLE disease activity
scores only, but not with global damage or extrarenal disease
activity scores. Among SLE patients, a higher uNGAL level
could diﬀerentiate between those with and without active
renal disease. uNGAL was found to correlate more strongly
with histologic activity scores than chronicity scores on
renal biopsies. Pitashny et al. [28] studied 70 adult SLE
patients (of whom 32 had active renal disease) and similarly
demonstrated that urinary NGAL levels were signiﬁcantly
higher in lupus nephritis than in nonrenal SLE patients or
healthy controls. Urine NGAL levels correlated with renal
but not with extrarenal SLE disease activity scores. Among
patients with lupus nephritis, urine NGAL levels correlated
signiﬁcantly with urine protein-to-creatinine ratios but not
with proteinuria, serum creatinine level, or conventional
lupus markers such as anti-dsDNA and complement levels.
Longitudinal data on NGAL in lupus nephritis are
recently available. Suzuki et al. [29] studied 85 pediatric
SLE patients and reported that both plasma and urine
NGAL levels were signiﬁcantly higher in patients with SLE
than juvenile idiopathic arthritis or healthy controls and
were unrelated to age, body weight, and height. Urine
but not plasma NGAL levels correlated with renal disease
activity scores. In patients with renal biopsy performed,
uNGAL levels were higher in diﬀuse proliferative than
membranouslupusnephritis.Patientswithworseningglobal
or renal disease activity had increased levels of uNGAL and
NGAL/creatinine. Increase in serum NGAL levels occurred
at a much less degree and was not statistically signiﬁcant.
The authors postulated that the sources of uNGAL in lupus
nephritis could be injured renal tubular cells, neutrophils, or
inﬂamed vasculature. They also emphasized that elevation of
uNGAL might be a reﬂection of renal injury/inﬂammation,
which was not speciﬁc to lupus renal disease.
Another longitudinal study on NGAL was carried out in
111 pediatric SLE patients [30]. SLE disease activity using
three standard disease activity indices and levels of plasma
and urinary NGAL were assessed quarterly. It was demon-
strated that a signiﬁcant increase in uNGAL/creatinine levels
of up to 104% was detected up to 3 months before worsening
oflupusnephritisasmeasuredbyallthethreediseaseactivity
indices. Plasma NGAL level also increased signiﬁcantly by
26% as early as 3 months before worsening of global SLE
diseaseactivity(byallthreediseaseindices)andrenalactivity
as measured by the BILAG renal score. Although the extent
of change in levels is much greater with urine compared to
plasma NGAL in this study, both biomarkers have a value in
predicting worsening of renal disease activity in childhood
lupus nephritis.
Finally, a more recent longitudinal study conﬁrmed
that urine NGAL level was a signiﬁcant predictor of renal
disease activity in SLE patients and a signiﬁcant predictor for
ﬂares in patients with a history of biopsy-proven nephritis
[31]. The speciﬁcity and sensitivity of urine NGAL level in
predicting renal ﬂares was higher than that of anti-dsDNA
titer.
3.3. Tumor Necrosis Factor-Like Inducer of Apoptosis
(TWEAK). Tumor necrosis factor- (TNF-) like inducer
of apoptosis (TWEAK) is a multifunctional cytokine that
belongs to the TNF-ligand superfamily. The main source
of soluble TWEAK is believed to be the macrophages.
TWEAK binds to its cognate receptor, Fn14, in various
tissues and mediates a number of physiological processes
such as cellular proliferation, survival, diﬀerentiation,
migration, and angiogenesis [32]. TWEAK/Fn14 interaction
has also been found to be involved in upregulation of
proinﬂammatory mediators and induction of cell death and
apoptosis (weak eﬀect) [18]. While TWEAK expression is
low in normal tissues, it is dramatically increased in the
context of inﬂammation and injury. Thus, it is thought that
TWEAK is important in the physiological processes of tissue
repair and regeneration but its expression is dysregulated in
chronic inﬂammatory states [33].
It is recently shown that ex vivo stimulation of murine
and human kidney cells by TWEAK induces the expression
of chemokines and inﬂammatory mediators such as MCP-1,
RANTES, IFN-gamma-induced protein 10 (IP-10), ICAM-1,
and VCAM-1 [34, 35], which are relevant to the induction of
inﬂammation through cellular recruitment and progression
of lupus nephritis. Another postulated pathogenetic mech-
anism of SLE is impaired clearance of apoptotic materials
by macrophages [36]. Increased expression of TWEAK on
activated lupus T cells has been shown to induce mono-
cyte/macrophage apoptosis, which may contribute to the
initiation of SLE through increasing the burden of apoptotic
materials [37].4 Journal of Biomedicine and Biotechnology
A pilot cross-sectional study demonstrated that urinary
TWEAK (uTWEAK) levels were signiﬁcantly higher in SLE
patients with active nephritis as compared to those with
inactive or no nephritis [38]. Moreover, uTWEAK levels
correlated with the renal SLE disease activity scores, serum
anti-dsDNA, and complement levels, as well as urine MCP-1
levels.However,uTWEAKdidnotcorrelatewithproteinuria,
suggesting that its increased level was not due to nonspeciﬁc
release as a result of glomerular damage.
A further multicenter longitudinal study involving
30 biopsy-proven lupus nephritis patients and ﬁve con-
trol groups (normal, nonrenal SLE, rheumatoid arthritis,
osteoarthritis and, non-SLE renal diseases) showed that
uTWEAK levels were signiﬁcantly higher in patients with
lupusnephritisthannonrenalSLE,rheumatoidarthritis,and
healthy controls [39]. As the uTWEAK levels in nonrenal
SLE patients were not signiﬁcantly diﬀerent from those of
the control groups, elevation of uTWEAK was unlikely a
feature of nonrenal lupus. However, there was some overlap
of the uTWEAK values of lupus nephritis patients with
controls, indicating that uTWEAK was not totally speciﬁc
for lupus renal disease. In a logistic regression model, it
was demonstrated that high uTWEAK levels (adjusted for
urinary creatinine) were independently associated with renal
involvement among patients with SLE, after adjustment
for age, sex, and ethnicity. uTWEAK was superior to
anti-dsDNA or complement levels in diﬀerentiating lupus
nephritis from nonrenal SLE patients. Although uTWEAK
levels correlated with renal SLE disease activity scores, there
was no signiﬁcant association between uTWEAK levels and
histological classes of lupus nephritis.
Thirteen patients with ﬂares of lupus nephritis were
longitudinally evaluated. The uTWEAK levels peaked at the
time of ﬂares, with an increasing trend before the ﬂares
and a decreasing trend after the ﬂare events. The uTWEAK
levels were signiﬁcantly higher during renal ﬂares than those
values 4–6 months before and after the ﬂares. A signiﬁcant
association between uTWEAK levels in SLE patients and
their renal disease activity scores over time was also found.
However, the small increase in the levels of uTWEAK 2
months before renal ﬂares from baseline was not statistically
signiﬁcant.
Overall,althoughuTWEAK is a promising biomarker for
lupus nephritis because of its high speciﬁcity for lupus renal
disease and good correlation with renal disease activity, it
may not be sensitive enough to predict a renal ﬂare early and
cannot replace the need for a renal biopsy.
3.4.UrineProteomics. Suzukietal.[40]utilitizedthesurface-
enhanced laser desorption/ionization time-of-ﬂight mass
spectrometry (SELDI-TOF MS) technology to isolate a panel
of urinary protein signature for pediatric patients with lupus
nephritis. Eight candidate peptides/proteins of molecular
mass from 2.7 to 133kD were identiﬁed. Four of these were
albumin or albumin fractional products and the others were
transferrin(TF),α1-acid-glycoprotein(AGP),ceruloplasmin
(CP), and lipocalin-type prostaglandin D-synthetase (L-
PGDS). In a preliminary study of 32 SLE patients, the peak
intensities of these biomarkers were signiﬁcantly greater in
patients with nephritis compared with controls and those
without nephritis [40] .T h eb i o m a r k e r ss t r o n g l yc o r r e l a t e d
withrenaldiseaseactivityandmoderatelywithrenaldamage.
Using a similar technique, Mosley et al. [41] identiﬁed
a panel of urine proteins and examined whether they were
able to diﬀerentiate between patients with active and inactive
lupus nephritis. In their study, it was found that proteins
with masses of 3340 and 3980 best distinguished active
from inactive renal disease in SLE. Multiple regression
scores calculated from a linear equation derived from the
discriminant analysis of these proteins were shown to predict
renal ﬂares and remission earlier than traditional clinical
markers in 6 patients with renal biopsy-conﬁrmed lupus
nephritis and serial urine samples tested.
In a further validation study, Suzuki et al. [42]m e a s u r e d
serially the urinary concentration of TF, AGP, CP, and L-
PGDS using immunonephelometry or ELISA in 98 children
with SLE and 30 controls with juvenile idiopathic arthritis.
All these urinary signature proteins were signiﬁcantly higher
in patients with active than inactive or no lupus nephritis,
as well as arthritis controls. By analyzing the area under
the receiver operating characteristic (ROC) curves, it was
shownthattheseurinarysignatureproteinsperformedbetter
than traditional renal markers such as complement levels,
creatinine clearance, and urine protein-to-creatinine ratio
in diﬀerentiating the presence of active lupus nephritis
as measured by the renal SLEDAI and BILAG scores.
Prospective data revealed signiﬁcant increases of urinary TF,
L-PGDS, and AGP occurred as early as 3 months before a
clinical diagnosis of worsening lupus nephritis. The result
appeared to be most promising for transferrin because its
level increased exclusively in those patients with worsening
nephritis but not in those with improved nephritis, stable
active or inactive nephritis, suggesting that it was a more
sensitive biomarker for a change in renal disease activity
than L-PGDS and AGP. There was no relationship between
urinary ceruloplasmin level and renal ﬂares. The predictive
value of a combination of these panel signature proteins for
renal ﬂares was not assessed in this study.
Hepcidin is a low-molecular-weight peptide hormone
mainly produced by the liver. Hepcidin has antimicrobial
activity, regulates iron metabolism, and is thought to be
involved in the pathogenesis of anemia of chronic illness
including chronic kidney disease [43]. Urinary excretion of
hepcidin is greatly enhanced in patients with iron overload,
infections, or inﬂammatory diseases [44]. Hepcidin is also
an acute phase reactant and is upregulated by interleukin-6
and interleukin-1 [45], which are cytokines implicated in the
pathogenesis of SLE. Using SELDI-TOF mass spectrometry,
Zhangetal.[46]identiﬁedthe20and25aminoacidisoforms
ofhepcidinaspotentialurinebiomarkersforlupusnephritis.
In a prospective study of 25 ﬂare cycles in 19 patients with
biopsy-proven lupus nephritis [46], it was shown that urine
hepcidin-20 concentration increased signiﬁcantly 4 months
before renal ﬂares and returned to baseline within 4 months.
Urine hepcidin-25, however, showed a reverse pattern of
expression, with concentration decreased during renal ﬂares
and returned to baseline 4 months after the ﬂare events.Journal of Biomedicine and Biotechnology 5
Taken together, serial urine proteomic analysis is potentially
useful in the early detection of ﬂares in lupus nephritis
and the monitoring of treatment response. However, further
validation studies are necessary.
3.5. Autoantibodies
3.5.1. Anti-C1q Antibodies. C1q is the ﬁrst component
of the classical pathway of the complement system. C1q
plays a crucial role in the clearance of immune complexes
and apoptotic bodies [47]. Prolonged exposure to C1q
epitopes to the immune system may induce autoimmune
phenomena. Both humans and mice with C1q deﬁciency
are at risk of developing lupus-like syndromes and immune-
mediated glomerulonephritis because of defective clearance
of apoptotic cells, autoantigens, and immune complexes
[48]. Anti-C1q autoantibodies were ﬁrst found in the sera
of patients with SLE although subsequently they could
have also been demonstrated in patients with hypocomple-
mentemic urticarial vasculitis, rheumatoid arthritis, human
immunodeﬁciency virus infection, non-SLE active glomeru-
lonephritis, and other organ-speciﬁc autoimmune diseases.
Anti-C1q antibodies are present in 20%–44% of patients
with SLE in cross-sectional studies and are associated with
thepresenceofnephritis[49–54].Titersofanti-C1qcorrelate
with global SLE disease activity scores [54–57]. In patients
with lupus nephritis, anti-C1q titer strongly correlates with
renal disease activity [51, 54, 58, 59], with a sensitivity of
44%–100% and a speciﬁcity of 70%–92% in various studies
[60].
Two recent prospective studies examined the value of
anti-C1q antibodies in monitoring of activity of lupus
nephritis and predicting ﬂares [61, 62]. Meyer et al. [61]
followed 70 SLE patients with and without evidence of
nephritis at baseline. In 15 patients who subsequently
developed nephritis, anti-C1q titers were elevated in all
(100%) of them compared to only 45% in those who
did not develop renal disease. The median anti-C1q titer
was also signiﬁcantly higher in patients with subsequent
renal disease than those without. With immunosuppressive
treatment, anti-C1q titers decreased but remained elevated
in some lupus nephritis patients. The corresponding ﬁgures
for elevation of anti-dsDNA titers in patients who did or
did not subsequently develop nephritis were 93% and 73%,
respectively. Anti-C1q did not correlate with anti-dsDNA
titer or SLE disease activity scores. Elevation of anti-C1q
titer had 50% positive predictive value and 100% negative
predictive value for the subsequent development of class IV
or V lupus nephritis.
Moroni et al. [62] measured the anti-C1q titers in
serial serum samples collected from 228 patients with lupus
nephritis over 6 years. In proliferative lupus nephritis, eleva-
tion of anti-C1q level predicted renal ﬂares with a sensitivity
and speciﬁcity of 81% and 71%, respectively, which was
only marginally better than other individual markers such
as anti-dsDNA, C3, and C4 levels. At multivariate analysis,
a combination of anti-C1q, C3, and C4 provided the best
performanceforpredictingrenalﬂares.Acombinationofthe
anti-C1q, anti-dsDNA, C3, and C4 tests had a good negative
predictive value, meaning that in the presence of normal
valuesofthese4tests,activelupusnephritiswasunlikely.The
sensitivity and speciﬁcity of anti-C1q elevation in predicting
renal ﬂares was much lower with the membranous type of
lupus nephritis. Up to 46% of ﬂares occurred with a normal
value of anti-C1q antibodies.
Although an elevation of anti-C1q titer is shown to
predict the development of lupus nephritis or renal ﬂares
in these studies, its performance is not signiﬁcantly better
than that of anti-dsDNA and complement levels. The high
negative predictive value of anti-C1q for severe renal disease
may be helpful for prognostic stratiﬁcation of SLE patients.
The usefulness of anti-C1q level in monitoring of lupus
activity in patients with negative anti-dsDNA antibodies has
to be further explored.
3.5.2. Antinucleosome Antibodies. Nucleosomes released by
apoptotic cells are major T and B cell autoantigens in
SLE [70]. Nucleosomes may act as bridging molecules
that recognize heparin sulphate/collagen components of the
glomerular basement membrane for the binding of antinu-
cleosome and other nephritogenic antibodies [71]. A recent
electronmicroscopicstudyofrenaltissuesfrompatientswith
lupus nephritis conﬁrms that autoantibodies colocalize with
electron-dense extracellular deposits of chromatin, suggest-
ing that intraglomerular membrane-associated nucleosomes
are targeted by nephritogenic autoantibodies [72].
A recent review summarizes 13 cross-sectional studies of
antinucleosome antibodies in lupus [79]. Antinucleosome
antibodies have a sensitivity ranging from 48 to 100% and
a speciﬁcity ranging from 90% to 99% for SLE. Antinu-
cleosome antibodies are associated with renal involvement
in some studies [80, 81] and their titers correlate with SLE
disease activity scores. The frequency of antinucleosome
antibodies in active SLE is similar to that of anti-dsDNA
antibodies, and the titers of these autoantibodies correlate
with each other in most studies.
The change in antinucleosome antibodies over time in
52 patients with active proliferative lupus nephritis treated
withhigh-doseglucocorticoidsandeithercyclophosphamide
or azathioprine in a prospective controlled clinical trial
was studied [82]. At baseline, patients with high titers
of the antinucleosome antibodies had signiﬁcantly higher
SLE disease activity scores. A rapid decline in the levels
of antinucleosome antibodies occurred after treatment but
renal ﬂares were not preceded by a rise of either the
antinucleosome or anti-dsDNA antibodies.
In another more recent study, 16 patients with biopsy-
conﬁrmed lupus nephritis were prospectively evaluated for
the relationship between antinucleosome titers and parame-
tersofrenaldiseaseactivity[92].Atbaseline,antinucleosome
titersweresigniﬁcantlyhigherinpatientsthancontrols.Over
the follow-up period, levels of antinucleosome correlated
with those of anti-dsDNA. Both antinucleosome and anti-
dsDNA antibody titers were signiﬁcantly associated with
urine protein-to-creatinine ratio and serum albumin level.6 Journal of Biomedicine and Biotechnology
Table 1: Serum biomarkers that correlate with lupus nephritis activity in cross-sectional studies.
Authors, year Biomarkers studied Main ﬁndings
Hoftman et al.,
2008 [63] MAGE-B2 antibodies Positive melanoma-associated antigen gene B2 (MAGE-B2) antibody associated
with higher SLE disease activity score and active lupus nephritis
Tan et al., 2008
[64] Anti-CRP antibody
IgG autoantibody against monomeric CRP prevalent in patients with lupus
nephritis and associated with SLE disease activity score and renal tubulointerstitial
lesions
Tucci et al., 2008
[65] Serum and urine IL-12 Glomerular expression of IL-12 predominantly occurs in class IV and V lupus
nephritis, serum and urine IL-12 higher in lupus nephritis than nonrenal SLE
Fu et al., 2008
[66]
Peripheral blood leukocyte
chemokine transcriptional
levels
Interferon-inducible chemokines in peripheral blood leucocytes higher in active
than inactive lupus nephritis and associated with SLE disease activity score
Morgan et al.,
2007 [67] Serum apoCIII Total apolipoprotein (apo) CIII levels signiﬁcantly elevated in lupus nephritis than
nonrenal SLE and controls
Sabry et al.,
2007 [68] Serum ICAM-1 Intracellular adhesion molecule (ICAM)-1 level signiﬁcantly higher in lupus
nephritis than nonrenal SLE and correlates with disease activity score
Tseng et al.,
2007 [69]
Antiendothelial cell
antibody
Antiendothelial cell antibody titer higher in active lupus nephritis than nonrenal
SLE and correlates with disease activity score
Table 2: Urine biomarkers that correlate with lupus nephritis activity in cross-sectional studies.
Authors, year Biomarkers studied Main ﬁndings
Kiani et al., 2009
[13]
Urine osteoprotegerin
(OPG)
OPG strongly associated with renal activity descriptors of the SELENA SLEDAI;
medium/high levels of OPG predictive of a urine protein/creatinine ratio of ≥0.5
Wang et al.,
2009 [73]
FOXP3 mRNA expression
in urinary sediments
FOXP3 mRNA expression signiﬁcantly higher in active than inactive lupus
nephritis, and in proliferative than nonproliferative nephritis, FOXP3 mRNA level
correlated with proteinuria and histological activity index; persistent elevation
associated with poor treatment response
Dhaun et al.,
2009 [74] Urine endothelin-1
Fractional excretion of endothelin-1 and urinary endothelin-1/creatinine ratio
higher in lupus nephritis than other chronic inﬂammatory renal diseases when
renal function is normal
En ghard et al.,
2009 [75]
Urine CXCR3+CD4+T
cells
Urinary CXCR3+CD4+ T cells are enriched in lupus nephritis and correlated with
SLE disease activity; higher concentration of urinary CXCR3+CD4+ T cells is
found in active than inactive nephritis
Tucci et al., 2008
[65] Serum and urine IL-12 Glomerular expression of IL-12 predominantly occurs in class IV and V lupus
nephritis; serum and urine IL-12 higher in lupus nephritis than nonrenal SLE
Wu et al., 2007
[76]
Urine VCAM-1, P-selectin,
TNFR-1, and CXCL16
Urinary VCAM-1, P-selectin, TNFR-1, and CXCL16 elevated in lupus nephritis,
correlating with proteinuria and SLE disease activity scores; urinary VCAM-1 and
CXCL16 showed superior speciﬁcity and sensitivity in distinguishing subjects with
active renal disease from the other SLE patients.
Hammad et al.,
2006 [77] Urine TGFβ-1 Urinary TGFβ-1 level signiﬁcantly higher in active than silent lupus nephritis,
correlated with anti-dsDNA and C3 levels
Chan et al., 2004
[78]
TGFβ and MCP-1 mRNA
expression in urine
sediments
Urinary TGFβ and MCP-1 mRNA expression correlated with histological activity
index on renal biopsy
Patients who achieved clinical remission had signiﬁcant
reduction in both antinucleosome and anti-dsDNA titers.
The predictive values of rising antinucleosome and anti-
dsDNA titers for renal ﬂares were not evaluated and com-
pared in this study, probably because of the relatively short
period ofobservation(mean37weeks).Althoughitisshown
that antinucleosome antibodies are useful in the monitoring
of lupus nephritis, there performance for predicting renal
ﬂares and outcome does not appear to be superior to anti-
dsDNA.
3.5.3. Anti-α-Actinin Antibodies. Alpha-actinin-4 belongs to
a family of actin-binding proteins that is expressed by
podocytesandmesangialcellsinrenaltissues[93].Inmurine
studies, the pathogenicity of nephritogenic anti-dsDNA or
antinucleosome antibodies is thought to be mediated by
cross-reactivity with α-actinin [94, 95]. A greater propor-
tion of anti-dsDNA IgG-binding antibodies puriﬁed from
patients with active lupus nephritis binds to α-actinin than
do those puriﬁed from sera of SLE patients without renal
disease [96].Journal of Biomedicine and Biotechnology 7
Table 3: Biomarkers that correlate with histological ﬁndings in lupus nephritis.
Authors, year Biomarkers studied Main ﬁndings
Oates et al.,
2008 [83]
Serum nitrate and nitrite
levels
Serum nitrate plus nitrite levels associated with SLE disease activity score; higher
nitrate/nitrite levels associated with histological proliferative renal lesions
Marks et al.,
2008 [84]
Glomerular MCP-1
expression
Glomerular monocyte chemoattractant protein-1 (MCP-1) expression higher in
class III and class IV than other classes of lupus nephritis
Nakayamada et
al., 2007 [85]
β1-integrin (CD29)
expression on T cells
CD29 expression on T cells upregulated in active SLE, especially in active diﬀuse
proliferative lupus nephritis
Avihingsanon et
al., 2006 [86]
Chemokine and growth
factor mRNA levels in
urinary sediments
Urine interferon-producing protein 10 (IP-10), CXCR3, TGF-β,a n dV E G Fm R N A
levels associated with class IV lupus nephritis
do Nascimento
et al., 2006 [87] Antiribosomal P antibody Frequency of antiribosomal P antibody higher in class V than other classes of lupus
nephritis
Oates et al.,
2005 [88] Urine glycoprotein panel An urinary glycoprotein panel may help to diﬀerentiate diﬀerent histological classes
of lupus nephritis
Table 4: Biomarkers that correlate with prognosis in lupus nephritis.
Authors, year Biomarkers studied Main ﬁndings
Izmirly et al.,
2009 [89]
mEPCR expression on
renal biopsy
Membrane expression of endothelial protein C receptor (mEPCR) in the renal
microvasculature in lupus nephritis associated with poor therapeutic response
Avihingsanon et
al., 2009 [90] VEGF expression Intrarenal vascular endothelial growth factor (VEGF) mRNA expression predicted
the deterioration of renal function in lupus nephritis
Marks et al.,
2008 [84]
Glomerular MCP-1
expression
Glomerular monocyte chemoattractant protein-1 (MCP-1) expression associated
with poor renal prognosis in pediatric lupus nephritis
Oates et al.,
2008 [83]
Serum nitrate and nitrite
levels
Higher serum nitrate plus nitrite levels associated with renal damage and treatment
failure in lupus nephritis
Martinez-
Lostao et al.,
2007 [91]
STAT-1 expression on renal
biopsy
Expression of STAT-1 in renal tissues associated with worse renal function and
outcome in class IV lupus nephritis
Avihingsanon et
al., 2006 [86]
Chemokine and growth
factor mRNA levels in
urinary sediments
Persistent elevation or increase of urine interferon-producing protein 10 (IP-10),
CXCR3, TGF-β, and VEGF mRNA levels associated with treatment failure in lupus
nephritis
Two cross-sectional studies have examined the associa-
tion between anti-α-actinin levels and disease activity in SLE
patients[97,98].Inone study[97],21%ofpatients withSLE
had positive anti-α-actinin antibodies and in these patients,
renal involvement was signiﬁcantly more common than
in those without the anti-α-actinin antibodies. In patients
with lupus nephritis, anti-α-actinin, but not anti-dsDNA,
levels, correlated with the SLEDAI scores. In the other study
[98], anti-α-actinin antibodies were detected in 20% of SLE
patients but were nonspeciﬁc for SLE because they were also
positive in other disease controls. Among patients with SLE,
anti-α-actinin antibody levels were signiﬁcantly higher in
those with renal ﬂares and correlated independently with
anti-dsDNA titers.
A recent prospective study by Manson et al. [92] did
not show any correlation between anti-α-actinin and the
anti-dsDNA or antinucleosome antibodies in a longitudinal
cohort of patients with active lupus nephritis. At baseline,
levels of anti-α-actinin were not signiﬁcantly higher in lupus
nephritis patients than in controls. Anti-α-actinin titers did
not correlate with proteinuria, serum albumin, or remission
status.
Although newer autoantibodies are available and useful
for the monitoring of lupus nephritis activity, they are
generally not more sensitive than conventional markers such
as anti-dsDNA and complements in predicting renal ﬂares.
The usefulness of these autoantibodies in the monitoring
of disease activity in subsets of SLE patients in whom
conventional markers are negative has yet to be studied.
The performance of a panel of conventional and novel
autoantibodies in the diagnosis, monitoring, and prognostic
stratiﬁcation of lupus nephritis has to be evaluated in the
future.
4.BiomarkersCorrelatingwithLupusRenal
ActivityinCross-SectionalStudies
Literature search reveals quite a number of cross-sectional
studies on the relationship between novel biomarkers and
activity of lupus nephritis [13, 63–69, 73–78]. These are
summarized in Table 1 (serum biomarkers) and Table 2
(urine biomarkers). Although some of these markers appear
to be promising, a common problem is the lack of validation8 Journal of Biomedicine and Biotechnology
in a larger longitudinal cohort of patients with lupus
nephritis. Moreover, results of individual biomarkers are
not conﬁrmed by independent groups of investigators. The
speciﬁcity of these biomarkers for SLE and for lupus renal
activity in particular, as well as their relationship with
histological disease activity, has to be explored further.
5.Biomarkers That Correlate with Histology or
PrognosisofLupusNephritis
Tables 3 and 4 summarize the biomarkers that have been
associated with histological classes or renal function deteri-
oration in lupus nephritis [83–91]. The quest continues for
biomarkersthatcandiﬀerentiatediﬀerenthistologicalclasses
of lupus nephritis. Although some of these biomarkers are
upregulated in the proliferative types of lupus nephritis,
they cannot at this juncture replace the need for standard
renal biopsy to delineate the histological features and the
relative degree of activity and chronicity of the renal lesions.
Further correlation studies between these biomarkers and
the histologic activity and chronicity scores are necessary to
evaluate their usefulness in prognostic stratiﬁcation.
6. Conclusions andTake-Home Messages
Although a large number of novel biomarkers have been
studiedinlupusnephritis,noneofthemhavebeenrigorously
validated in large-scale longitudinal cohorts of patients
with diﬀerent ethnic background. It is unlikely at this
juncture that a candidate biomarker stand-alone can replace
conventional clinical parameters to monitor disease progress
and detect early renal ﬂares. Urine biomarkers appear
to be more encouraging than serum biomarkers possibly
because they are the direct products or consequences of
kidney inﬂammation or injury. Future directions in SLE
biomarker research should focus on a combination of novel
markers with conventional clinical parameters to enhance
the sensitivity and speciﬁcity for the prediction of renal ﬂares
and prognosis in lupus nephritis.
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